PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study finds high Rx burden for bipolar patients

2014-02-04
(Press-News.org) Contact information: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Study finds high Rx burden for bipolar patients

A study of 230 patients with bipolar I disorder whose symptoms were severe enough to warrant admission to a Rhode Island psychiatric hospital in 2010 reveals that more than a third were there despite taking four or more psychiatric medications. Including medicines for other conditions, such as cardiometabolic diseases, the average patient came to the hospital taking six different drugs.

The study quantifies a difficult outcome for many patients with this difficult-to-treat disorder, said study lead author Lauren Weinstock of the Alpert Medical School of Brown University and of Butler Hospital, where the patients were admitted: They accrue a high burden of prescriptions each with their own side effects, with often unknown interactions, and with a complexity that can result in not taking the medications as prescribed. This medication burden also includes high overall cost to patients and the healthcare system.

Yet for those patients who've needed to come to the hospital, these complex combinations of drugs haven't proven sufficiently effective, Weinstock said.

The study, published online Feb. 1 in the journal Psychiatry Research, also reports the likelihood of a high medication burden was significantly greater for women than men.

"The high rate of complex polypharmacy reflects the enormous challenge of symptom management that we currently face for bipolar disorder," said Weinstock, an assistant professor of psychiatry and human behavior at Brown. "Without many treatment alternatives, this is where we are as a field. It is important for us to advance science and treatment of bipolar disorder so that this medication burden can be minimized for our patients."

Weinstock, who studies psychotherapy as a complement to medical treatment at Butler, said she and her colleagues became motivated to quantify the pharmacological burden for those with biploar disorder after witnessing it anecdotally among patients.

'Complex polypharmacy'

Weinstock and her co-authors therefore compiled data from patients' hospital admission records in the calendar year 2010. The only inclusion criteria were being 18 or older, and having a diagnosis of bipolar I disorder at hospital admission and discharge.

"The data aren't confounded by someone's active participation in a research study," Weinstock said. "We wanted to measure what was happening in routine community practice."

What they found is that when they came to the hospital, patients were taking an average of 3.3 psychotropic drugs and an average of 5.9 drugs overall. Nearly one in five patients weren't on any psychotropic drugs, but more than half were taking 3 or more and more than a third were taking four or more, meeting the definition of "complex polypharmacy."

The complex polypharmacy rate of 36 percent is higher than in a few previous studies that looked at bipolar patients, Weinstock said, because those studies did not always include all psychotropic medications, such as the commonly prescribed antianxiety medications.

Weinstock noted that because no clinical trial of bipolar medications has ever tested more than two drugs in combination, prescribing three or four exceeds practices supported by the field.

"By definition that's not evidence-based treatment," she said.

No prior studies had looked at the total medication burden, rather than just that of pyschotropics. It's important to do so, Weinstock said, because cardiometabolic diseases, in particular, are often concurrent with bipolar disorder. Among the 230 patients in the study, for example, about half had such medical problems.

More so for women

Women, the data showed, were 58 percent of the total patients, but 68 percent of those with complex polypharmacy. Women were more likely to be on an antidepressant, antianxiety medication, and on stimulants, all of which which remain somewhat controversial in bipolar disorder treatment, Weinstock said.

The proportion of women taking an antidepressant (43 percent) was nearly twice that of men (23 percent). The significance of the gender disparities in the study endured even after statistically controlling for depressive symptoms in their diagnosis.

"Women weren't prescribed more medications just because they were more likely to be depressed," Weinstock said. "This finding raises the question of what other factors may influence higher rates of polypharmacy among female patients, such as patient or provider characteristics."

But the study does not provide information that could reveal why that is.

Still, combined with other studies and epidemiological data, the study points to a trend that needs improving, Weinstock and her co-authors wrote: "This increased reliance on polypharmacy does not appear to be contributing to decreased rates of illness chronicity or functional impairment in BD."



INFORMATION:



In addition to Weinstock other authors are Brandon Gaudiano, Gary Epstein-Lubow, Katherine Tezanos, Cintly E. Celis-deHoyos and Ivan Miller.

The National Institute of Mental Health supported the study (grant: K23MH079907).



ELSE PRESS RELEASES FROM THIS DATE:

Carnegie Mellon model predicts growth, death of membership-based websites

2014-02-04
PITTSBURGH—Facebook, now celebrating its 10th anniversary, is a proven success in what the late Nobel laureate ...

Are you big pharma's new target market?

2014-02-04
This news release is available in French. Montreal, February 4, 2014 — By 2018, it is estimated that the global pharmaceutical ...

Where do lizards in Qatar live? First distribution maps for the state

2014-02-04
The state of Qatar occupies a small peninsula of 11,500 km2 within the Arabian Peninsula. Both Qatar's population and economy have increased rapidly during the last decades, thus putting ...

In vitro innovation: Testing nanomedicine with blood cells on a microchip

2014-02-04
Designing nanomedicine to combat diseases is a hot area of scientific research, primarily for treating cancer, but very little is known in the context of atherosclerotic disease. ...

How safe is the enemy of a citrus-threatening pest?

2014-02-04
RIVERSIDE, Calif. — The Asian citrus psyllid (ACP) can spread the lethal and ...

Dartmouth study provides first evidence of common brain code for space, time, distance

2014-02-04
A new Dartmouth study provides the first evidence that people use the same brain circuitry to figure out space, time and social distances. The findings, which help reveal ...

Stock prices are predictable

2014-02-04
A new study from the University of Iowa shows evidence that stock price movements are, in fact, predictable during short windows. The study by researchers in ...

Research: It's more than just the science

2014-02-04
When putting together a team of scientists to work on a problem, it makes sense to bring together the best and brightest in the field, right? Well, maybe not. In a newly published paper, a team of researchers from ...

Researchers discover new hormone receptors to target when treating breast cancer

2014-02-04
Boston, MA – According to the United States Centers for Disease Control and Prevention, breast cancer ...

Queen's University cancer specialist's drive to improve survival rates for every European citizen

2014-02-04
Queen's University Belfast's world renowned cancer specialist, Professor Patrick Johnston, whose work has transformed cancer care in Northern Ireland, is now leading ...

LAST 30 PRESS RELEASES:

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

[Press-News.org] Study finds high Rx burden for bipolar patients